Live Breaking News & Updates on குழந்தை நோய்

Stay updated with breaking news from குழந்தை நோய். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FibroGen Receives Rare Pediatric Disease Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy


FibroGen Receives Rare Pediatric Disease Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
April 15, 2021 07:00 ET
| Source:
FibroGen, Inc
FibroGen, Inc
San Francisco, California, UNITED STATES
SAN FRANCISCO, April 15, 2021 (GLOBE NEWSWIRE) FibroGen, Inc. (NASDAQ: FGEN) announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company’s anti-CTGF antibody, pamrevlumab, for the treatment of patients with Duchenne muscular dystrophy (DMD). Pamrevlumab has also received Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in two Phase 3 trials for the treatment of DMD.   ....

United States , Michael Tung , Jennifer Harrington , Mark Eisner , Exchange Commission , Fibrogen Inc , Drug Administration , Rare Pediatric Disease , Fast Track , Chief Medical Officer , Rare Pediatric Disease Designation , Pediatric Disease , Biologics Licensing Application , Priority Review Voucher , Annual Report , Nasdaq Fgen , ஒன்றுபட்டது மாநிலங்களில் , மைக்கேல் துங் , ஜெனிபர் ஹாரிங்டன் , குறி ஈஸ்னர் , பரிமாற்றம் தரகு , ரேர் குழந்தை நோய் , வேகமாக டிராக் , தலைமை மருத்துவ அதிகாரி , ரேர் குழந்தை நோய் பதவி , குழந்தை நோய் ,